153789-13-0

Basic information

• Product Name: 7-Azabicyclo[4.1.0]heptane-7-carboxylic acid, 1,1-dimethylethyl ester
• Synonyms: tert-butyl 7-azabicyclo<4.1.0>heptane-7-carboxylate;(+-)-7-(tert-butoxycarbonyl)-7-aza-bicyclo-[4.1.0]-cycloheptane;AZA007;7-(tert-butoxycarbonyl)-7-azabicyclo[4.1.0]heptane;7-Azabicyclo[4.1.0]heptane-7-carboxylic acid,1,1-dimethylethyl ester;N-Boc-cyclohexanoaziridine
• CAS NO: 153789-13-0
• Molecular Formula: C11H19NO2
• Molecular Weight: 197.277
• Mol File: 153789-13-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 7-Azabicyclo[4.1.0]heptane-7-carboxylic acid, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Azabicyclo[4.1.0]heptane-7-carboxylic acid, 1,1-dimethylethyl ester(153789-13-0)
• EPA Substance Registry System: 7-Azabicyclo[4.1.0]heptane-7-carboxylic acid, 1,1-dimethylethyl ester(153789-13-0)

Safety Data

• Hazardous Substances Data: 153789-13-0(Hazardous Substances Data)

Upstream product

• 286-18-0 7-azabicyclo[4.1.0]heptane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 71559-13-2 2-azido cyclohexanol 
• 286-20-4 cyclohexane-1,2-epoxide 
• 477584-30-8 tert-butyl 2-hydroxycyclohexylcarbamate 
• 477584-30-8 tert-butyl [(1RS,2RS)-2-hydroxycyclohexyl]carbamate 

Downstream Products

• 359678-99-2 tert-butyl (1RS,2RS)-2-(phenylthio)cyclohexylcarbamate 

Relevant articles and documents

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

Synthesis of β-fluoroamines by Lewis base catalyzed hydrofluorination of aziridines

Lewis base catalysis promotes the in situ generation of amine-HF reagents from benzoyl fluoride and a non-nucleophilic alcohol. The hydrofluorination of aziridines to provide β-fluoroamines using this latent HF source is described. This protocol displays a broad scope with respect to aziridine substitution and N-protecting groups. Examples of regio- and diastereoselective ring opening to access medicinally relevant β-fluoroamine building blocks are presented.

Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases

Disclosed herein are compounds of Formula I and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These diseases and disorders include hypotension, septic shock, toxic shock syndrome, hemodialysis, IL-2 therapy such as in in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn, eczema or psoriasis and respiratory conditions such as bronchitis, asthma, oxidant-induced lung injury and acute respiratory distress (ARDS), glomerulonephritis, restenosis, inflammatory sequelae of viral infections, myocarditis, heart failure, atherosclerosis, osteoarthritis, rheumatoid arthritis, septic arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension, retinitis and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis.